Skip to main content
. 2019 Oct 23;7(11):482. doi: 10.3390/microorganisms7110482

Table 1.

Phenotypic characteristics of the transconjugants of the eight carbapenem-resistant and colistin-resistant E. coli.

Antibiotics tested Transconjugants selected by rifampin plus imipenem plus colistin E. coli C600
Minimum inhibitory concentration (μg/ml)
Cir007 1 Cir012 Cir020 Cir033 Cir035 Cir100 Cir115
Amikacin > 32 (R1) > 32 (R) > 32 (R) > 32 (R) > 32 (R) > 32 (R) > 32 (R) ≤ 8 (S)
Gentamicin > 8 (R) > 8 (R) > 8 (R) > 8 (R) > 8 (R) > 8 (R) > 8 (R) ≤ 2 (S)
Tobramycin > 8 (R) > 8 (R) > 8 (R) > 8 (R) > 8 (R) > 8 (R) > 8 (R) ≤ 2 (S)
Ertapenem > 2 (R) > 2 (R) > 2 (R) > 2 (R) > 2 (R) > 2 (R) 2 (R) ≤ 0.25 (S)
Imipenem > 8 (R) > 8 (R) > 8 (R) > 8 (R) > 8 (R) 1 (S) 8 (R) 0.5 (S)
Meropenem > 8 (R) > 8 (R) > 8 (R) > 8 (R) > 8 (R) 1 (S) 4 (R) ≤ 0.13 (S)
Cefazolin > 16 (R) > 16 (R) > 16 (R) > 16 (R) > 16 (R) > 16 (R) > 16 (R) 4 (S)
Cefuroxime > 16 (R) > 16 (R) > 16 (R) > 16 (R) > 16 (R) > 16 (R) > 16 (R) 16 (R)
Cefoxitin > 16 (R) > 16 (R) > 16 (R) > 16 (R) > 16 (R) > 16 (R) > 16 (R) 8 (S)
Ceftazidime > 32 (R) > 32 (R) > 32 (R) > 32 (R) > 32 (R) > 32 (R) > 32 (R) ≤ 1 (S)
Ceftriaxone > 32 (R) > 32 (R) > 32 (R) > 32 (R) > 32 (R) > 32 (R) > 32 (R) ≤ 1 (S)
Cefepime > 16 (R) > 16 (R) > 16 (R) 16 (R) > 16 (R) 16 (R) 8 (R) ≤ 1 (S)
Amoxicillin/clavulanate > 32/16 (R) > 32/16 (R) > 32/16 (R) > 32/16 (R) > 32/16 (R) 32/16 (R) 32/16 (R) ≤ 8/4 (S)
Ampicillin/sulbactam >16/8 (R) >16/8 (R) >16/8 (R) >16/8 (R) > 16/8 (R) > 16/8 (R) >16/8 (R) 8/4 (S)
Piperacillin/tazobactam >64/4 (R) >64/4 (R) >64/4 (R) >64/4 (R) >64/4 (R) >64/4 (R) >64/4 (R) ≤ 4/4 (S)
Colistin > 4 (R) > 4 (R) 4 (R) 4 (R) 4 (R) > 4 (R) > 4 (R) ≤ 1 (S)
Chloramphenicol > 16 (R) > 16 (R) > 16 (R) ≤ 4 (S) ≤ 4 (S) > 16 (R) ≤ 4 (S) ≤ 4 (S)
Moxifloxacin > 2 (R) > 2 (R) > 2 (R) ≤ 0.5 (S) ≤ 0.5 (S) > 2 (R) ≤ 0.5 (S) ≤ 0.5 (S)
Ciprofloxacin > 4 (R) > 4 (R) > 4 (R) ≤ 0.5 (S) ≤ 0.5 (S) 2 (I) ≤ 0.5 (S) ≤ 0.5 (S)
Levofloxacin > 8 (R) > 8 (R) > 8 (R) ≤ 1 (S) ≤ 1 (S) 2 (S) ≤ 1 (S) ≤ 1 (S)
Norfloxacin > 8 (R) > 8 (R) > 8 (R) ≤ 2 (S) ≤ 2 (S) 4 (S) ≤ 2 (S) ≤ 2 (S)
Tetracycline > 8 (R) > 8 (R) > 8 (R) ≤ 2 (S) ≤ 2 (S) > 8 (R) ≤ 2 (S) ≤ 2 (S)
Minocycline 4 (S) 4 (S) 4 (S) ≤ 1 (S) 2 (S) 16 (R) 2 (S) ≤ 1 (S)
Trimethoprim/sulfamethoxazole > 4/76 (R) > 4/76 (R) > 4/76 (R) ≤1/19 (S) ≤ 1/19 (S) ≤ 1/19 (S) ≤1/19 (S) ≤ 1/19 (S)
Aztreonam ≤ 2 (S) ≤ 2 (S) ≤ 2 (S) ≤ 2 (S) ≤ 2 (S) ≤ 2 (S) ≤ 2 (S) ≤ 2 (S)
Fosfomycin > 128 (R) > 128 (R) > 128 (R) ≤ 16 (S) ≤ 16 (S) ≤ 16 (S) > 128 (R) ≤ 16 (S)
Nitrofurantoin ≤ 16 (S) 32 (S) ≤ 16 (S) ≤ 16 (S) ≤ 16 (S) > 64 (R) ≤ 16 (S) ≤ 16 (S)
Tigecycline ≤ 1 (S) ≤ 1 (S) ≤ 1 (S) ≤ 1 (S) ≤ 1 (S) ≤ 1 (S) ≤ 1 (S) ≤ 1 (S)

1 Note: Cir007, Cir012, Cir020, Cir033, Cir035, Cir100, and Cir115 represent the transconjugant of RXD007, RXD012, RXD020, RXD033, RXD035, RXD100, and RXD115, respectively. R: Resistant; S: susceptible; I: intermediately resistant.